Maxime RangerPhD, MBA

Chief Executive Officer

Giiant Pharma

Maxime is the CEO of giiant pharma inc, after spending 4 years as General Partner at AmorChem. As a serial entrepreneur, Maxime founded the first AmorChem’s spin-out company, Mperia Therapeutics in 2016. He also played a leading role in the creation and management of Inversago Pharma, SemaThera and Neurasic Therapeutics, to name a few. He is still an active contributor to the Quebec biotech ecosystem through his participation and leadership in Montreal InVivo committees, in addition to being adjunct professor of the Pharmacy School at the University of Montreal.

Maxime played different drug development roles in Montreal biotech companies, namely Ecopia Biosciences (became Thallion Pharma, acquired by Bellus Health), Bioxalis Medica (acquired by Procyon) and Labopharm (acquired by Paladin Labs/Endo). In 2008, he launched his first start-up, Nuvector, where its key asset reached Phase 2 trial with BiolineRx. In 2011, Maxime founded gIcare pharma and brought its lead candidate up to Phase 2a completion. In addition, Maxime spent some time as entrepreneur-in-residence at Univalor, expanding his expertise in technology transfer and licensing. He holds a PhD in Chemistry from Université Laval and performed a postdoctoral fellowship at Stanford University. In addition, he completed a joint Executive MBA at UQAM and Université Paris-Dauphine.